
https://www.science.org/content/blog-post/noisy-numbers
# Noisy Numbers (November 2008)

## 1. SUMMARY

This short commentary describes increasing uncertainty in numerical data as drug discovery progresses from chemistry to clinical trials. The author begins with the precision of chemistry and analytical measurements, explaining how molecular weights and mass spectra can be determined to several decimal places. This precision degrades at each subsequent phase: protein assays provide fuzzier measurements, cellular assays introduce more complexity and variability, and animal studies show even greater spread due to variables ranging from absorption and metabolism to environmental factors. In human clinical trials, this progression culminates in a challenge to extract interpretable signals from noisy data, as compounded by individual human differences and clinical complexities. The central theme captures the inherent trade-offs between early predictability and late-stage real-world relevance.

## 2. HISTORY

After 2008, drug discovery faced persistent and often worsening forms of the measurement "noise" described. Several major companies experienced high-profile late-stage failures, drawing attention to poor translational predictability. In 2011, a widely cited *Nature Reviews Drug Discovery* study found that more than half of Phase III failures resulted from lack of efficacy—a direct manifestation of the noise problem: promising in vitro and animal results did not reliably translate into measurable benefits in humans.

Industry-wide efforts tried to mitigate these issues, but facts on the ground remained stubborn. The rise of personalized medicine (e.g., biomarker-driven trials) and adaptive trial designs after 2010 attempted, in part, to reduce noise by enriching patient populations and adjusting trial parameters based on early signals. Genomics and systems biology were harnessed to better understand the mechanisms behind variable responses and to improve patient stratification. The FDA's drug approval success rate for novel agents moving from Phase I to approval fluctuated, generally staying under 15%, reflecting continuing challenges in translating early signals into robust clinical benefits.

Despite methodological advances and better statistical tools, fundamentally noisy processes—bioavailability, clearance, off-target effects, and human variability—still dominated attrition rates. High-throughput screening and computational approaches improved early-stage precision, yet animal-to-human translation remained a major bottleneck. Some of the largest pharmaceutical companies faced costly write-downs and pipeline restructuring due to unexpected Phase III failures, demonstrating that the problem described in 2008 remained diagnostically accurate.

## 3. PREDICTIONS

The article focuses more on descriptive commentary than explicit predictions, but it implicitly frames expectations about reproducibility and translation in drug discovery. In that regard:

- **No systematic escape from noise**: The piece describes escalating uncertainty from chemistry to clinical trials. The empirical outcome over the next decade was that this pattern persisted largely unmitigated. High attrition rates and translational failures remained endemic. While assays became more sophisticated, heterogeneity and complex interactions continued to complicate clinical signal detection.
- **Early-stage precision as false comfort**: The author implies that chemical precision does not ensure later success. This proved correct; computational chemistry and high-throughput screens improved early hit rates, but these gains often washed out in cellular and animal studies, and even more so in humans. Many mechanistically promising candidates failed due to factors not captured by in vitro assays.
- **Progress despite noise**: The essay closes with clinical trials "desperately hoping" to find signals. Trials did, in fact, continue to succeed, but the industry gradually adjusted by adopting larger trial sizes, better statistical methods, and biomarker enrichment to increase signal-to-noise ratios. Adaptive designs and basket trials emerged, acknowledging rather than eliminating the noise.

## 4. INTEREST

Rating: **6/10**

This is a concise, insightful articulation of a persistent problem in drug development. While not groundbreaking, it resonates with enduring translational challenges and remains relevant to current R&D practice.


----
_model_params = {'model': 'nex-agi/deepseek-v3.1-nex-n1:free', 'input': '20081120-noisy-numbers.txt', 'reasoning': {'effort': 'high'}, 'text': {'verbosity': 'medium'}, 'prompt-template': 'prompt-template-2'}_